Microsoft Corporation

Investor focus on Microsoft's AI revenue growth will only intensify, analyst says

Oppenheimer expects Microsoft stock to rise 20%. Why does he think they are undervalued?

Newmont Corporation

Barrick Gold Corporation

Hecla Mining Company

One of the analysts' recommendations is to keep at least half of the portfolio allocated to precious metals in gold

Investors are looking for "new gold" and buying other precious metals. How to build a portfolio?

Apple Inc.

He was seen as a potential successor to Tim Cook and played a key role in the Apple Watch project


A key Apple executive leaves at a difficult moment. Should investors be worried?


NVIDIA Corporation

Since April, the chipmaker's stock is up more than 70%

"Historic moment": Nvidia is the first in the world to reach a $4 trillion market value


Mercedes-Benz Group AG

Volkswagen AG

Bayerische Motoren Werke AG

Berlin is pushing a scheme that Brussels calls "delusional"

The EU and the US are close to an agreement on incentives for the auto industry. Which companies will benefit?

The first half of 2025 has been a real seesaw for investors in small-cap stocks: ETFs investing in European and Asian small-cap stocks soared, while their U.S. counterparts often balanced near zero or went negative;

Rally outside the U.S.: small-cap ETF leaders and outsiders in the first half of 2025

ProKidney Corp.

The capitalization of biotech ProKidney, which treats kidney failure in diabetic patients, rose sixfold to $1.8 billion in a single day. The company touted the successful results of a trial of its drug, but analysts are cautious.&nbsp;

Shares of pharma company ProKidney soared 500% after the trial. Is it worth buying them?

Merck & Co., Inc.

Amazon.com, Inc.

First Solar, Inc.

Daily review and forecast of events on the US stock market from&nbsp;Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: US tariff pressure and Fed meeting minutes in focus

Data

A gauge of investor sentiment from Bloomberg Intelligence “approached manic” in June. This could portend a relative downturn in the small-cap space, however.

Why small-cap investors should be wary of 'manic' sentiment in markets

In recent years, South and Southeast Asia have attracted investors as a trove of new ideas and high-growth companies, with economies across the region undergoing rapid expansion and transformation. While investor attention often remains focused on large corporations, smaller firms in Asia are also delivering impressive growth and innovation, frequently achieving success within their respective niches. The MSCI Asia Apex Small Cap 200 index, which tracks the performance of the 200 largest and most liquid small caps in the broader MSCI AC Asia ex Japan Small Cap index, has soared 79.8% over the past three years and is up nearly 14.0% year to date. By comparison, the MSCI AC Asia Pacific index has risen 11.8% and 13.6% over the same periods, respectively.

Three small caps that reflect different aspects of Asia's growth and transformation

Beam Global

Beam Global CEO Desmond Wheatley brings more than three decades of executive experience to the table, having built and led companies ranging from startups to publicly traded firms generating $70 million in annual revenue, according to his LinkedIn <a href="https://www.linkedin.com/in/desmondwheatley/">profile</a>. “For a long time, I worked for companies that were polluting the environment. I spent a lot of time in the Middle East, working for people whose values I don't support now,” he said in an interview with Oninvest.

Head of clean tech innovator Beam Global tells Oninvest about plans and Trump effect


Hims & Hers Health, Inc.

Freedom Broker now recommends clients buy shares of Hims &amp; Hers Health, a telehealth company, in the wake of a recent dip. The mid-cap stock has lost 35% of its market value due to a canceled partnership with pharma giant Novo Nordisk, which alleges that Hims&nbsp;&amp; Hers put patient safety at risk through “deceptive” marketing and sold a knockoff version of its drug Wegovy. Despite this, Freedom Broker analysts think Hims &amp; Hers stock will bounce back quickly.&nbsp;

Freedom Broker says buy Hims & Hers after cancellation of tie-up with Novo Nordisk

QuantumScape Corporation

QuantumScape, a mid-cap maker of solid-state rechargeable lithium metal batteries for EVs, has been soaring of late, but&nbsp;Baird Equity Research&nbsp;<a href="https://www.marketwatch.com/story/quantumscapes-stock-is-still-on-a-tear-but-buyer-beware-analyst-says-36ea9613?mod=newsviewer_click">sees</a>&nbsp;a number of risks for investors. The stock&nbsp;<a href="https://finance.yahoo.com/quote/QS/">added</a>&nbsp;78% in the last two days thanks to the&nbsp;the <a href="https://finance.yahoo.com/news/quantumscape-achieves-major-milestone-cobra-203000396.html">announcement</a>&nbsp;of a new manufacturing process for a key battery component.&nbsp;But Baird analyst Ben Kallo said in a note he wants "additional details on the go-to-market strategy before becoming more constructive." Currently, Kallo's target price implies downside for the stock.